Following the DVPs first 10 investments, Emma Palmer Foster, Director of Discovery Park Ventures, and Martino Picardo, Director of DPV and Chairman of Discovery Park, share their learnings and insights into life science investing.
Magrietha Mallinson, Global Vertical Lead, Health at DP World discusses unlocking the potential of Africa's pharmaceutical market in our latest EPM Online insight.
Guillaume Wallart, CEO, CellQuest explores how diagnostics models can make autologous cell therapy manufacturing work in our latest EPM online insight.
In our first interview series of the year with Lonza, we spoke with Dr. Simon Wagschal, Associate Director, Advanced Chemistry Technologies, Lonza Small Molecules Global R&D and Dr. Aaron Johnson, Manager, Cheminformatics & Data Science, Lonza.
Dr. Danial Arkwell, Head of Global Key Accounts, Pharma at Envirotainer highlights the vital role of efficient logistics in getting orphan drugs to patients in desperate need.
There is a real opportunity for AI to maximise Life Sciences companies’ investment in regulatory data management. ArisGlobal’s Agnes Cwienczek & Renato Rjavec set out practical examples of AI and Generative AI delivering tangible benefits.
With more gene therapy trials securing approval and getting underway globally, innovators are focusing on developing viral vector carrier technologies that are safer and more predictable.
Paul Knight, Managing Director of CME Automation Systems analyses one of the biggest challenges facing the life sciences industry: how to implement automated ‘just-in-time’ clinical supply chains.
Maria Elena Gasperini, Director of Sustainability Life Sciences, Jacobs discuses the ways in which the biopharma industry can build a sustainable future in our latest EPM Online Insight.
It’s long been a concern for scientists and regulators that drugs are intended for use by anyone but are predominantly tested on one group – white men. Richard Staines reports on how this could change.
